Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States

Published:2016-12-13 Issue:4 Volume:24 Page:268-279
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Elbasha E.¹,Greaves W.¹,Roth D.²,Nwankwo C.¹

Affiliation:

1. Merck & Co., Inc.; Kenilworth NJ USA

2. University of Miami Miller School of Medicine; Miami FL USA

Funder

Merck

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12639/fullpdf

Reference64 articles.

1. Prevalence of chronic kidney disease in the United States;Coresh;JAMA,2007

2. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010;Denniston;Ann Intern Med,2014

3. Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients;Shimokura;Infect Control Hosp Epidemiol,2011

4. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?;Fabrizi;J Viral Hepat,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes;Diabetes, Obesity and Metabolism;2023-07-06

2. A Cost-effectiveness Analysis of Adherence Promotion Strategies to Improve Rejection Rates in Adolescent Kidney Transplant Recipients;American Journal of Kidney Diseases;2022-09

3. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review;Frontiers in Public Health;2022-05-13

4. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China;Frontiers in Pharmacology;2021-10-15

5. Incorporating Patients’ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study;MDM Policy & Practice;2021-07